Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancerDavid M O'Malley, Ana Oaknin, Bradley J Monk, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defectsMihaela Aldea, Laurent Lam, Emeline Orillard, et al.
BMJ Open|June 4, 2025
Protocol for a global menopause priority setting partnershipZachary Nash, Monica M Christmas, Toto Gronlund, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
Maturitas|July 18, 2021
Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statementMargaret Rees, Johannes Bitzer, Antonio Cano, et al.
Bulletin Du Cancer|April 27, 2021
[Vaccination against COVID-19 in patients with solid cancer: Review and point of view from a French oncology inter-group (CGO, TNCD, UNICANCER)]David Tougeron, Barbara Seitz-Polski, Maxime Hentzien, et al.
Bulletin Du Cancer|March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Analytical Chemistry|April 13, 2022
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGSCeline Callens, Francois-Clement Bidard, Anaïs Curto-Taribo, et al.
Journal of the National Cancer Institute|August 3, 2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECOJacobus Pfisterer, Béatrice Weber, Alexander Reuss, et al.
The Lancet. Oncology|April 2, 2016
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 studyFrançois Bertucci, Mahmoud Fekih, Aurélie Autret, et al.
Pageof 11